📅 PUBMED DAILY TRIAGE — 2026-10-29 Window: 2026-10-28T09:00:00Z → 2026-10-29T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: 91 | Candidates evaluated: 106 High priority: 2 | Standard: 36 | Low/archive: 0 | Unsolicited finds: 3 Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)
Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma): No high-priority finds today (best candidate scored 7/10).
CBC-based diagnostics and machine learning in hematology
CBC-based diagnostics and machine learning in hematology: No high-priority finds today (best candidate scored 6/10).
Early cancer detection (liquid biopsy, ctDNA, cfDNA)
Early cancer detection (liquid biopsy, ctDNA, cfDNA): No high-priority finds today (best candidate scored 7/10).
AI/ML in clinical diagnostics and imaging
AI/ML in clinical diagnostics and imaging: No high-priority finds today (best candidate scored 7/10).
Precision oncology and genomic medicine
Precision oncology and genomic medicine: No high-priority finds today (best candidate scored 7/10).
Novel therapeutics: immunotherapy, CAR-T, targeted therapy
Novel therapeutics: immunotherapy, CAR-T, targeted therapy: No high-priority finds today (best candidate scored 7/10).
Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
PMID:42949535 · A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity · 8/10 · Acmopatide improved glycemic control and produced clinically meaningful weight loss without diabetic ketoacidosis or severe hypoglycemia over 16 weeks
Aging, longevity, and population health
Aging, longevity, and population health: No high-priority finds today (best candidate scored 7/10).
Rare diseases with high unmet need
PMID:42951601 · Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA) · 8/10 · The first approved disease-modifying therapy for MPS IIIA improved modeled cognitive outcomes and lowered cerebrospinal-fluid heparan sulfate, with substantial liver-enzyme elevations and serious adverse events requiring follow-up
🟢⚪ STANDARD (5-7) — Top by Topic
Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)
PMID:42950247 · CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States · 7/10 · Public Health PMID:42950253 · Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma · 7/10 · Treatment Innovation PMID:42951113 · IDH2 p.R172 mutation Predicts Superior Outcomes in IDH-mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome patients undergoing Allogeneic Hematopoietic Cell Transplantation: a retrospective study from the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC) · 7/10 · Genomics/Precision Medicine PMID:42950111 · Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France · 6/10 · Treatment Innovation PMID:42951621 · [Inherited anemias: current approaches to diagnosis and treatment] · 5/10 · Genomics/Precision Medicine
CBC-based diagnostics and machine learning in hematology
PMID:42950648 · From cell images to clinical insight: Clinically grounded explainable classification of peripheral blood and bone marrow cells with cross-modal learning · 6/10 · Diagnostics
Early cancer detection (liquid biopsy, ctDNA, cfDNA)
PMID:42950585 · Risk stratification by circulating tumor DNA-based pretreatment genomic profile and post-operative molecular residual disease detection in resectable colorectal oligometastases: PRECISION, a prospective multicenter study · 7/10 · Genomics/Precision Medicine PMID:42950862 · Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling · 7/10 · Genomics/Precision Medicine PMID:42951388 · DNA Methylation Profiling: Current and Emerging Uses in Gynecologic Pathology · 5/10 · Diagnostics
AI/ML in clinical diagnostics and imaging
PMID:42951254 · Harnessing Clinical Characteristics to Identify High-Risk of Drug-induced QTc Prolongation in Hospitalized Patients · 7/10 · Diagnostics PMID:42949277 · A generalizable 3D dose prediction across heterogeneous cohorts: A framework developed for the 2025 AAPM GDP-HMM challenge · 6/10 · Diagnostics PMID:42950648 · From cell images to clinical insight: Clinically grounded explainable classification of peripheral blood and bone marrow cells with cross-modal learning · 6/10 · Diagnostics PMID:42951037 · Speech-based differentiation of unipolar and bipolar depression across scripted reading and interview questions · 6/10 · Diagnostics PMID:42951245 · Towards a digital twin for precision diabetes care: a phenotypic mapping and virtual representation of a person living with type 1 diabetes in the SFDT1 study · 6/10 · Genomics/Precision Medicine
Precision oncology and genomic medicine
PMID:42950585 · Risk stratification by circulating tumor DNA-based pretreatment genomic profile and post-operative molecular residual disease detection in resectable colorectal oligometastases: PRECISION, a prospective multicenter study · 7/10 · Genomics/Precision Medicine PMID:42950862 · Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling · 7/10 · Genomics/Precision Medicine PMID:42949538 · TRACER: response-protected cross-domain alignment of cancer pharmacogenomic models with patient tumors · 5/10 · Drug Development PMID:42950362 · Integrated genomic and transcriptomic profiling reveals distinct molecular features of colorectal cancer in an Indian cohort · 5/10 · Genomics/Precision Medicine PMID:42950850 · An Inverse-Selection-Probability Weighted Approach for Real-World Progression-Free Survival With Left-Truncated Clinico-Genomic Data · 5/10 · Genomics/Precision Medicine
Novel therapeutics: immunotherapy, CAR-T, targeted therapy
PMID:42950247 · CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States · 7/10 · Public Health PMID:42950111 · Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France · 6/10 · Treatment Innovation PMID:42950831 · Arginine rewires eIF4F translation initiation to overcome fever-induced CAR T cell dysfunction · 6/10 · Treatment Innovation PMID:42949972 · Ionic liquid-mediated cellular loading for whole tumor cell vaccines · 5/10 · Drug Development PMID:42950024 · A systematic pan-cancer analysis of intratumoral microbiota-derived epitopes to inform cancer immunotherapy and prevention · 5/10 · Drug Development
Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
PMID:42951018 · Comparing SGLT2 Inhibitors on Incident Major Adverse Kidney Events in Type 2 Diabetes: A Target Trial Emulation · 7/10 · Treatment Innovation PMID:42951303 · Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12-Month Real-World Results · 7/10 · Treatment Innovation PMID:42950223 · Mind Your Heart-A Web-Based Dietary Approaches to Stop Hypertension Diet and Mindful Eating Intervention for Working Adults at Elevated Cardiovascular Risk: Pilot Randomized Controlled Trial · 5/10 · Prevention PMID:42950309 · Pharmacist-led intervention for optimal heart failure medications: A pilot randomized controlled trial · 5/10 · Treatment Innovation
Aging, longevity, and population health
PMID:42950244 · Impact of Chatbot-Based Cognitive Training on Cognitive Function and White Matter Integrity in Cognitively Unimpaired Older Adults: Randomized Controlled Trial · 7/10 · Prevention PMID:42950852 · Age-Dependent Reversal of Sex Differences in Severe Long-Term Care Dependency: A Six-Year Analysis of Integrated Healthcare and Long-Term Care Data · 6/10 · Public Health PMID:42950853 · Predicting Future Long-Term Care Dependency with Explainable Artificial Intelligence Using Administrative Healthcare Data · 6/10 · Public Health PMID:42949332 · PPARγ/P21 Signaling Mediates Butyrate-Driven Protection against Aging-Related Endothelial Dysfunction: A Novel Effect of Soybean Polysaccharide via the Gut-Vascular Axis · 5/10 · Prevention PMID:42950221 · AI-Based Grading of Facial Aging Signs and Prediction of Visible Age From Standardized Facial Images: Algorithm Development and Internal Evaluation Study · 5/10 · Diagnostics
Rare diseases with high unmet need
PMID:42950981 · An EMA perspective on the regulatory approval of Waskyra®, the first gene therapy for the treatment of Wiskott-Aldrich Syndrome · 5/10 · Treatment Innovation PMID:42951338 · Extending the clinical utility of exome sequencing: reanalysis, variant reclassification, and dynamic reporting in molecular diagnosis · 5/10 · Genomics/Precision Medicine PMID:42951621 · [Inherited anemias: current approaches to diagnosis and treatment] · 5/10 · Genomics/Precision Medicine
💡 UNSOLICITED FINDS
PMID:42950355 · Simplified Chlamydia trachomatis screening in France: positivity rate from a large community laboratory network in 2025 · 7/10 · Prescription-free testing reached many young adults with high positivity, and multisite sampling identified infections that urogenital testing alone would have missed PMID:42951567 · Dual-mode cross-validating biosensor based on a biomimetic Molecular Burr probe for quantitative autoimmune disease evaluation · 6/10 · The dual-mode assay agreed closely with a commercial assay and a multiparameter model achieved an AUC of 0.967 for autoimmune hepatitis PMID:42949310 · A collaborative quality improvement project to enhance knowledge of preventive health screening and services among new migrants and refugees in the Australian Capital Territory · 5/10 · Trusted-language education improved knowledge of sexual, cervical, and breast-health screening services across most modules
📊 TODAY'S BREAKDOWN
- By research category: Diagnostics 8 | Drug Development 4 | Genomics/Precision Medicine 8 | Prevention 3 | Public Health 5 | Treatment Innovation 10
- By evidence maturity: Exploratory 24 | Potentially Practice-Changing 1 | Validated 13
- By watchlist topic:
- Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma): 15 reviewed / 5 kept / highest 7
- CBC-based diagnostics and machine learning in hematology: 1 reviewed / 1 kept / highest 6
- Early cancer detection (liquid biopsy, ctDNA, cfDNA): 6 reviewed / 3 kept / highest 7
- AI/ML in clinical diagnostics and imaging: 15 reviewed / 7 kept / highest 7
- Precision oncology and genomic medicine: 12 reviewed / 5 kept / highest 7
- Novel therapeutics: immunotherapy, CAR-T, targeted therapy: 15 reviewed / 7 kept / highest 7
- Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk: 13 reviewed / 5 kept / highest 8
- Aging, longevity, and population health: 7 reviewed / 5 kept / highest 7
- Rare diseases with high unmet need: 12 reviewed / 4 kept / highest 8
- Sentinel scan (unsolicited finds): 10 reviewed / 3 kept / highest 7
- By source type: peer_reviewed 38 | preprint 0
- Topics with zero 8+ articles this run: Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma); CBC-based diagnostics and machine learning in hematology; Early cancer detection (liquid biopsy, ctDNA, cfDNA); AI/ML in clinical diagnostics and imaging; Precision oncology and genomic medicine; Novel therapeutics: immunotherapy, CAR-T, targeted therapy; Aging, longevity, and population health; Sentinel scan (unsolicited finds)
🔧 RUN NOTES
- No window expansion was needed because the run retained at least five relevant records.
- Independent caps were hit for hematologic malignancies, AI/ML diagnostics, novel therapeutics, and sentinel; each capped ordered candidate list is recorded in Output A.
- ESummary covered all 100 unique selected PMIDs. EFetch covered 91 unique PMIDs; nine individually retried records remained explicitly missing and were not retained.
- Classification used PubMed abstracts and metadata only; no PMC or publisher full text was reviewed.
- This rerun regenerated the complete daily JSON and did not send Telegram alerts.